Dhitiwat Changpradub

Does Vancomycin Resistance Increase Mortality? Clinical Outcomes and Predictive Factors for Mortality in Patients with Enterococcus faecium Infections

Jatapat Hemapanpairoa, Dhitiwat Changpradub, Sudaluck Thunyaharn et al. · Antibiotics · 2021 · 39 citations · Full text

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial

Pedro Cahn, Richard Kaplan, Paul E. Sax et al. · The Lancet HIV · 2017 · 35 citations · Full text

Treatment And Prevention, Antiviral Drug Development, Clinical Trials +9

Effect of standard dose paracetamol versus placebo as antipyretic therapy on liver injury in adult dengue infection: a multicentre randomised controlled trial

Vasin Vasikasin, Thanawith Rojdumrongrattana, Worayon Chuerboonchai et al. · The Lancet Global Health · 2019 · 29 citations · Full text

Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials

Chloe Orkin, Jean‐Michel Molina, Pedro Cahn et al. · The Lancet HIV · 2023 · 25 citations · Full text

First-line Therapy, Open-label Extensions, Antiviral Drug Development +7

Colistin plus Sulbactam or Fosfomycin against Carbapenem-Resistant<i>Acinetobacter baumannii</i>: Improved Efficacy or Decreased Risk of Nephrotoxicity?

Weerayuth Saelim, Dhitiwat Changpradub, Sudaluck Thunyaharn et al. · Infection and Chemotherapy · 2021 · 23 citations · Full text